Hill-Rom Holdings Inc. (NYSE:HRC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “Post a promising third quarter by Hill-Rom, we are upbeat about the company to remain on a solid growth trajectory over the near term. The company’s year-over-year outcome was impressive along with record level of gross margin. Based on several positive catalysts, we expect the company to expand geographically in the coming quarters. Notably, in the last reported quarter, Hill-Rom posted strong growth in both Asia-Pacific and the U.S. While we remain impressed with the company’s increased bottom-line guidance for fiscal 2016, the revenue guidance was quite discouraging. Moreover, Hill-Rom’s persistent poor performance in the International front, especially in the Middle East and Latin America keeps us concerned. Unfortunately no near term improvement can be expected in the existing capital crunch condition that eventually led to economic and political downturns in these economies.”

HRC has been the topic of a number of other research reports. Morgan Stanley raised shares of Hill-Rom Holdings from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $54.00 to $62.00 in a research note on Thursday, June 16th. KeyCorp reaffirmed a “buy” rating and issued a $59.00 price target on shares of Hill-Rom Holdings in a research note on Thursday, June 23rd. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Hill-Rom Holdings has an average rating of “Buy” and an average price target of $61.83.

Shares of Hill-Rom Holdings (NYSE:HRC) opened at 59.75 on Tuesday. The company has a market capitalization of $3.91 billion, a P/E ratio of 61.53 and a beta of 1.06. The firm has a 50-day moving average of $58.36 and a 200-day moving average of $52.27. Hill-Rom Holdings has a one year low of $42.99 and a one year high of $60.48.

Hill-Rom Holdings (NYSE:HRC) last announced its quarterly earnings results on Thursday, August 4th. The medical technology company reported $0.81 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.76 by $0.05. Hill-Rom Holdings had a net margin of 2.47% and a return on equity of 16.62%. The firm had revenue of $655.40 million for the quarter, compared to analyst estimates of $647.75 million. During the same quarter in the previous year, the firm posted $0.62 earnings per share. The business’s revenue was up 38.1% on a year-over-year basis. Equities research analysts expect that Hill-Rom Holdings will post $3.33 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 30th. Stockholders of record on Friday, September 16th will be issued a $0.17 dividend. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 1.14%. Hill-Rom Holdings’s dividend payout ratio (DPR) is presently 73.91%.

Several hedge funds have recently bought and sold shares of the stock. Acrospire Investment Management LLC purchased a new position in shares of Hill-Rom Holdings during the first quarter worth $111,000. BlueMountain Capital Management LLC increased its position in shares of Hill-Rom Holdings by 36.5% in the second quarter. BlueMountain Capital Management LLC now owns 2,343 shares of the medical technology company’s stock worth $118,000 after buying an additional 626 shares during the last quarter. Envestnet Asset Management Inc. increased its position in shares of Hill-Rom Holdings by 30.1% in the first quarter. Envestnet Asset Management Inc. now owns 2,454 shares of the medical technology company’s stock worth $123,000 after buying an additional 568 shares during the last quarter. LS Investment Advisors LLC increased its position in shares of Hill-Rom Holdings by 67.4% in the second quarter. LS Investment Advisors LLC now owns 3,783 shares of the medical technology company’s stock worth $191,000 after buying an additional 1,523 shares during the last quarter. Finally, Bluestein R H & Co. purchased a new position in shares of Hill-Rom Holdings during the second quarter worth $202,000. Institutional investors own 83.11% of the company’s stock.

Hill-Rom Holdings Company Profile

Hill-Rom Holdings, Inc is a medical technology company. The Company offers patient care solutions that improve clinical and economic outcomes in advancing mobility, wound care and prevention, clinical workflow, surgical safety and efficiency, and respiratory health areas. Its segments include North America, Surgical and Respiratory Care, International and Welch Allyn.

5 Day Chart for NYSE:HRC

Get a free copy of the Zacks research report on Hill-Rom Holdings (HRC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Hill-Rom Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.